Kezar Life Sciences
Kezar Life Sciences develops first-in-class, small molecule therapies targeting key intracellular proteins to treat autoimmune diseases and cancers. The company advances two therapeutic approaches: Selective Immunoproteasome Inhibition and Protein Secretion Inhibition.
Services
Kezar Life Sciences focuses on developing first-in-class, small molecule therapies designed to inhibit multiple disease-driving cellular pathways. These therapies are targeted at identifying and addressing key intracellular proteins. The company advances two key therapeutic approaches: Selective Immunoproteasome Inhibition and Protein Secretion Inhibition. Both approaches are aimed at treating conditions such as autoimmune diseases and various types of cancers by targeting the underlying cellular mechanisms.
Therapeutic Approaches
Kezar Life Sciences employs two differentiated therapeutic approaches: Selective Immunoproteasome Inhibition and Protein Secretion Inhibition. Selective Immunoproteasome Inhibition, exemplified by their drug Zetomipzomib (KZR-616), treats autoimmune diseases by modulating the immune system without direct immunosuppression. Protein Secretion Inhibition is another approach where they target and halt the secretion of proteins contributing to cancers and autoimmune diseases, as demonstrated by their drug KZR-261 for advanced/metastatic solid tumors.
Key Products
Kezar Life Sciences has developed several key products, including KZR-261 and Zetomipzomib (KZR-616). KZR-261 is a first-in-class small molecule inhibitor targeting the Sec61 translocon, designed to block the expression of proteins crucial for cancer cell proliferation, metastasis, and immune evasion. Zetomipzomib is a selective immunoproteasome inhibitor aimed at a variety of autoimmune diseases, promising a 'pipeline in a drug' approach that can broadly modulate the immune system when dysregulated.
Clinical Trials
Kezar Life Sciences is conducting clinical trials to advance their therapeutic approaches. KZR-261 has initiated a Phase 1 clinical trial for advanced/metastatic solid tumors, aiming to evaluate its safety and efficacy. Additionally, Zetomipzomib (KZR-616) is being studied for its potential to treat a broad range of autoimmune conditions by offering a steroid sparing effect and modulating the immune system.
Company Location
Kezar Life Sciences is headquartered at 4000 Shoreline Court, Suite 300, South San Francisco, CA 94080. The company is committed to developing therapies that are both safe and effective for serious diseases, impacting patients and their families. Despite ongoing advancements, Kezar Life Sciences does not currently offer an expanded access program for their investigational therapies.